Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.58 |
| ▸ | METAP1 | P53582 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31296097 | 0.84 | CYP19A1 (0.57) | ACHEHTR2CHTR1ACYP19A1 | |
| SCHEMBL6528990 | 0.84 | ACHE (0.62) | ACHEMETAP1HTR2AHTR2CDRD3 | |
| SCHEMBL8556555 | 0.83 | ACHE (0.60) | ACHEMETAP1HTR2AHTR2CDRD3 | |
| SCHEMBL1853465 | 0.82 | ACHE (0.63) | ACHEMETAP1HTR2AHTR2CDRD3 | |
| SCHEMBL11770524 | 0.78 | METAP1 (0.58) | ACHEMETAP1HTR2AHTR2CDRD3 | |
| SCHEMBL9324677 | 0.78 | METAP1 (0.63) | ACHEMETAP1HTR2AHTR2CDRD3 | |
| SCHEMBL20359102 | 0.78 | METAP1 (0.58) | ACHEMETAP1HTR2AHTR2CDRD3 | |
| SCHEMBL30641036 | 0.77 | ACHE (0.54) | ACHEMETAP1HTR2AHTR2CDRD3 | |
| SCHEMBL21064364 | 0.74 | METAP1 (0.58) | ACHEMETAP1HTR2AHTR2CDRD3 | |
| SCHEMBL3077121 | 0.74 | METAP1 (0.54) | ACHEMETAP1HTR2AHTR2CDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150371009-A1 | DRUG IDENTIFICATION MODELS AND METHODS OF USING THE SAME TO IDENTIFY COMPOUNDS TO TREAT DISEASE | CHEN JAKE YUE (US) | 2015-12-24 | — | — | US | disclosed |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | MEDIVATION NEUROLOGY, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| US-7563808-B2 | Methods for treating cognitive impairments or dementia | EISAI CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20090131480-A1 | Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia | EISAI CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090042939-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042940-A1 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | EISAI CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080167343-A1 | Methods and compositions using cholinesterase inhibitors | EISAI CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20070129402-A1 | Donepezil; pharmacokinetics; single-dose administration of the formulation to a patient provides a blood plasma level profile with a dosage-corrected Cmax | EISAI RESEARCH INSTITUTE (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | ACHE 20/4885METAP1 1131/4885HTR2A 1220/4885 |
| US-20080167343-A1 | Methods and compositions using cholinesterase inhibitors | PSEN1, BACE1, PSENEN | ACHE 26/4885METAP1 757/4885HTR2A 55/4885 |
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | ACHE, CHRNA5, CHRNA2 | ACHE 1/4885METAP1 313/4885HTR2A 1353/4885 |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | PSEN2, APP, PSEN1 | ACHE 12/4885METAP1 783/4885HTR2A 185/4885 |
| US-20090131480-A1 | Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia | CHRNA5, GRIN1, GRIK5 | ACHE 33/4885METAP1 807/4885HTR2A 135/4885 |
| US-20070129402-A1 | Donepezil; pharmacokinetics; single-dose administration of the formulation to a patient provides a blood plasma level profile with a dosage-corrected Cmax | CYP3A5, SLC6A2, SLC6A4 | ACHE 4/4885METAP1 549/4885HTR2A 82/4885 |
| US-20090042939-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | ACHE 26/4885METAP1 757/4885HTR2A 55/4885 |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | NOTCH3, NOTCH2, NOTCH4 | ACHE 156/4885METAP1 313/4885HTR2A 1912/4885 |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | ACHE 26/4885METAP1 757/4885HTR2A 55/4885 |
| US-20090042940-A1 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | PSEN1, BACE1, PSENEN | ACHE 26/4885METAP1 757/4885HTR2A 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.